Quantum Computing Revenue Reaches $9.5 Million, Exceeding First-Half Total
Key Facts
Quantum Computing Inc. reported results on November 9 for the third quarter ended September 30, 2026, posting revenue of $9.5 million, above first-half revenue of $9.2 million, according to the company. Its adjusted loss was $0.07 per share, compared with Zacks consensus estimates for a loss of $0.08. But that was greater than the $0.05 per-share loss in the year-earlier quarter, according to Zacks. The company recorded a net loss of $15.1 million for the quarter. The results thus combined a per-share earnings beat and sales growth with continued losses as the business expanded.
Quarterly revenue rose from $384,000 in the year-earlier period, according to the company's comparison, while gross profit was $428,000 and gross margin was 4.5%. The company said revenue growth was driven by Luminar Semiconductors, NuCrypt and NHanced, which it acquired during the first half of 2026. Those businesses include sales of photonic components and quantum communications products, as well as advanced packaging services. The services cater to the aerospace, government and industrial markets, according to the company. The filing shows Luminar contributed revenue of $12.8 million and an operating loss of $6.6 million from its acquisition through September 30. NuCrypt contributed revenue of $0.7 million and an operating loss of $0.1 million, while NHanced recorded revenue of $3.9 million and an operating loss of $2.6 million during the period since its acquisition.
Operating expenses totaled $29.0 million in the third quarter, up from $10.5 million in the year-earlier period. The company attributed the increase mainly to employee, research and development, sales and marketing costs, as well as about $1 million in acquisition expenses. The company's filing with the U.S. Securities and Exchange Commission showed an operating loss of $28.585 million, compared with $10.404 million a year earlier. Meanwhile, interest and other income was $13.0 million, versus $3.5 million in the third quarter of 2025. The company said the increase mainly reflected interest earned on larger cash and investment balances. Net cash used in operating activities was $35.0 million in the first nine months of 2026, compared with $19.3 million in the same period a year earlier.
The company ended the quarter with about $1.3 billion in cash and cash equivalents, investments and accrued interest, according to its statement. The amount included $174.3 million in cash and cash equivalents and $1.1 billion in short- and long-term investments, including accrued interest. Its contracted backlog stood at about $39.1 million on September 30. The company defines this backlog as the value of contracted work expected to be performed, subject to contract terms. In the first nine months of 2026, net cash used in investing activities was $533.2 million. The company attributed this to net purchases of $350.6 million in available-for-sale securities, acquisition payments of $168.8 million and capital expenditures of $13.9 million.
On commercial expansion, the company announced an agreement during the quarter with INmune Bio to apply its Dirac quantum optimization technology to clinical and biological data alongside artificial intelligence and traditional analytics. It said the agreement represents its first commercial customer in the pharmaceutical and biotechnology sector. In September, it also announced a framework agreement with Qatar's Hamad Bin Khalifa University to support education, research and joint marketing in quantum technologies. The agreement includes cloud access to the Dirac-3 quantum optimization system. The company lists these activities among its priorities for expanding commercial operations, increasing manufacturing and advancing its quantum roadmap. Chief Executive Yuping Huang said: "Our priorities are clear: grow our commercial business, scale manufacturing and advance our quantum roadmap."
On a cumulative revenue basis, the company's sales totaled $18.742 million in the nine months ended September 30, 2026, compared with $484,000 in the same period of 2025, according to its filing with the U.S. Securities and Exchange Commission. Over the same period, net cash used in operations rose to $35.0 million from $19.3 million a year earlier. In the same filing, company management concluded that disclosure controls and procedures were not effective as of September 30, 2026, citing material weaknesses in internal control over financial reporting. These matters form part of the quarter's picture alongside revenue growth and the expansion of its acquired business base. Huang said the company still had much work to do despite its clear priorities. A recording of the results call was scheduled to remain available through November 23, 2026.